drugset / Trial / NCT01525173
A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (IOP) lowering medication.
Timeline
- Start
- 2012-01
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bimatoprost | Other / unclassified | 0.01 % | Other |
| Comparator | Brimonidine | Small molecule | 0.1 % | Other |
| Comparator | Latanoprost | Small molecule | 0.005 % | Other |